Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs

Nicolás M. Ballarini; Thomas Burnett; Thomas Jaki; Christoper Jennison; Franz König; Martin Posch

doi:10.1002/sim.8949

Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs

Nicolás M. Ballarini, Thomas Burnett, Thomas Jaki, Christoper Jennison, Franz König, Martin Posch

Research output: Contribution to journal › Article › peer-review

8 Citations (SciVal)

Abstract

We design two-stage confirmatory clinical trials that use adaptation to find the subgroup of patients who will benefit from a new treatment, testing for a treatment effect in each of two disjoint subgroups. Our proposal allows aspects of the trial, such as recruitment probabilities of each group, to be altered at an interim analysis. We use the conditional error rate approach to implement these adaptations with protection of overall error rates. Applying a Bayesian decision-theoretic framework, we optimize design parameters by maximizing a utility function that takes the population prevalence of the subgroups into account. We show results for traditional trials with familywise error rate control (using a closed testing procedure) as well as for umbrella trials in which only the per-comparison type 1 error rate is controlled. We present numerical examples to illustrate the optimization process and the effectiveness of the proposed designs.

Original language	English
Pages (from-to)	2939-2956
Number of pages	18
Journal	Statistics in Medicine
Volume	40
Issue number	12
Early online date	29 Mar 2021
DOIs	https://doi.org/10.1002/sim.8949
Publication status	Published - 30 May 2021

Bibliographical note

Funding Information:
information H2020 Marie Sk?odowska-Curie Actions, 633567; Innovative Medicines Initiative, 853966; Medical Research Council, MR/M005755/1; National Institute for Health Research, NIHR-SRF-2015-08-001Nicol?s Ballarini is supported by the EU Horizon 2020 Research and Innovation Programme, Marie Sklodowska-Curie grant No 633567. Thomas Jaki is supported by the National Institute for Health (NIHR-SRF-2015-08-001) and the Medical Research Council (MR/M005755/1). Franz K?nig and Martin Posch are members of the EU Patient-Centric Clinical Trial Platform (EU-PEARL) which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking, grant No 853966. This Joint Undertaking receives support from the EU Horizon 2020 Research and Innovation Programme, EFPIA, Children's Tumor Foundation, Global Alliance for TB Drug Development, and SpringWorks Therapeutics. The views expressed in this publication are those of the authors. The funders and associated partners are not responsible for any use that may be made of the information contained herein.

.

Keywords

Bayesian optimization
conditional error function
subgroup analysis
utility function

ASJC Scopus subject areas

Epidemiology
Statistics and Probability

Access to Document

10.1002/sim.8949Licence: CC BY

Cite this

@article{4b7afc5c8d4b43bd8e3da03260cc198b,

title = "Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs",

abstract = "We design two-stage confirmatory clinical trials that use adaptation to find the subgroup of patients who will benefit from a new treatment, testing for a treatment effect in each of two disjoint subgroups. Our proposal allows aspects of the trial, such as recruitment probabilities of each group, to be altered at an interim analysis. We use the conditional error rate approach to implement these adaptations with protection of overall error rates. Applying a Bayesian decision-theoretic framework, we optimize design parameters by maximizing a utility function that takes the population prevalence of the subgroups into account. We show results for traditional trials with familywise error rate control (using a closed testing procedure) as well as for umbrella trials in which only the per-comparison type 1 error rate is controlled. We present numerical examples to illustrate the optimization process and the effectiveness of the proposed designs.",

keywords = "Bayesian optimization, conditional error function, subgroup analysis, utility function",

author = "Ballarini, {Nicol{\'a}s M.} and Thomas Burnett and Thomas Jaki and Christoper Jennison and Franz K{\"o}nig and Martin Posch",

note = "Funding Information: information H2020 Marie Sk?odowska-Curie Actions, 633567; Innovative Medicines Initiative, 853966; Medical Research Council, MR/M005755/1; National Institute for Health Research, NIHR-SRF-2015-08-001Nicol?s Ballarini is supported by the EU Horizon 2020 Research and Innovation Programme, Marie Sklodowska-Curie grant No 633567. Thomas Jaki is supported by the National Institute for Health (NIHR-SRF-2015-08-001) and the Medical Research Council (MR/M005755/1). Franz K?nig and Martin Posch are members of the EU Patient-Centric Clinical Trial Platform (EU-PEARL) which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking, grant No 853966. This Joint Undertaking receives support from the EU Horizon 2020 Research and Innovation Programme, EFPIA, Children's Tumor Foundation, Global Alliance for TB Drug Development, and SpringWorks Therapeutics. The views expressed in this publication are those of the authors. The funders and associated partners are not responsible for any use that may be made of the information contained herein. .",

year = "2021",

month = may,

day = "30",

doi = "10.1002/sim.8949",

language = "English",

volume = "40",

pages = "2939--2956",

journal = "Statistics in Medicine",

issn = "0277-6715",

publisher = "John Wiley and Sons Inc.",

number = "12",

}

TY - JOUR

T1 - Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs

AU - Ballarini, Nicolás M.

AU - Burnett, Thomas

AU - Jaki, Thomas

AU - Jennison, Christoper

AU - König, Franz

AU - Posch, Martin

N1 - Funding Information: information H2020 Marie Sk?odowska-Curie Actions, 633567; Innovative Medicines Initiative, 853966; Medical Research Council, MR/M005755/1; National Institute for Health Research, NIHR-SRF-2015-08-001Nicol?s Ballarini is supported by the EU Horizon 2020 Research and Innovation Programme, Marie Sklodowska-Curie grant No 633567. Thomas Jaki is supported by the National Institute for Health (NIHR-SRF-2015-08-001) and the Medical Research Council (MR/M005755/1). Franz K?nig and Martin Posch are members of the EU Patient-Centric Clinical Trial Platform (EU-PEARL) which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking, grant No 853966. This Joint Undertaking receives support from the EU Horizon 2020 Research and Innovation Programme, EFPIA, Children's Tumor Foundation, Global Alliance for TB Drug Development, and SpringWorks Therapeutics. The views expressed in this publication are those of the authors. The funders and associated partners are not responsible for any use that may be made of the information contained herein. .

PY - 2021/5/30

Y1 - 2021/5/30

N2 - We design two-stage confirmatory clinical trials that use adaptation to find the subgroup of patients who will benefit from a new treatment, testing for a treatment effect in each of two disjoint subgroups. Our proposal allows aspects of the trial, such as recruitment probabilities of each group, to be altered at an interim analysis. We use the conditional error rate approach to implement these adaptations with protection of overall error rates. Applying a Bayesian decision-theoretic framework, we optimize design parameters by maximizing a utility function that takes the population prevalence of the subgroups into account. We show results for traditional trials with familywise error rate control (using a closed testing procedure) as well as for umbrella trials in which only the per-comparison type 1 error rate is controlled. We present numerical examples to illustrate the optimization process and the effectiveness of the proposed designs.

AB - We design two-stage confirmatory clinical trials that use adaptation to find the subgroup of patients who will benefit from a new treatment, testing for a treatment effect in each of two disjoint subgroups. Our proposal allows aspects of the trial, such as recruitment probabilities of each group, to be altered at an interim analysis. We use the conditional error rate approach to implement these adaptations with protection of overall error rates. Applying a Bayesian decision-theoretic framework, we optimize design parameters by maximizing a utility function that takes the population prevalence of the subgroups into account. We show results for traditional trials with familywise error rate control (using a closed testing procedure) as well as for umbrella trials in which only the per-comparison type 1 error rate is controlled. We present numerical examples to illustrate the optimization process and the effectiveness of the proposed designs.

KW - Bayesian optimization

KW - conditional error function

KW - subgroup analysis

KW - utility function

UR - http://www.scopus.com/inward/record.url?scp=85103222847&partnerID=8YFLogxK

U2 - 10.1002/sim.8949

DO - 10.1002/sim.8949

M3 - Article

AN - SCOPUS:85103222847

SN - 0277-6715

VL - 40

SP - 2939

EP - 2956

JO - Statistics in Medicine

JF - Statistics in Medicine

IS - 12

ER -

Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this